Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ONO-2020
- Development stage
- Phase 2
- Lead developer
- Ono Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ONO-2020 is an orally active small molecule inhibitor of lysine-specific demethylase 1 (LSD1), an epigenetic regulator, developed by Ono Pharmaceutical. It is currently in Phase 2 clinical trials for the treatment of mild to moderate Alzheimer's disease (AD) and agitation associated with AD dementia. By inhibiting LSD1, ONO-2020 aims to modulate gene expression patterns to improve cognitive functions, such as memory and cognition, and to manage behavioral symptoms like agitation in patients with dementia. The drug's development program includes studies in both healthy participants and patients with AD to evaluate its safety, tolerability, pharmacokinetics, and efficacy.
02
Targets
KDM1A (LSD1)
Beyond the preview
Go deeper on ONO-2020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ONO-2020.